Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism?

Giuseppe Sancesario, Luigi Antonio Morrone, Vincenza D'Angelo, Valentina Castelli, Davide Ferrazzoli, Francesco Sica, Alessandro Martorana, Roberto Sorge, Federica Cavaliere, Giorgio Bernardi, Mauro Giorgi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Second messenger cAMP and cGMP represent a key step in the action of dopamine that modulates directly or indirectly their synthesis. We aimed to verify whether levodopa-induced dyskinesias are associated with changes of the time course of levodopa/dopamine stimulated cAMP and cGMP levels, and/or with changes of their catabolism by phosphodiesterase activity in rats with experimental hemiparkinsonism. Microdialysis and tissue homogenates of the striatal tissues demonstrated that extracellular and intracellular cAMP/cGMP levels were lower in dyskinetic animals during the increasing phase of dyskinesias compared to eukinetic animals, but cAMP/cGMP levels increased in dyskinetic animals during the phase of decreasing and extinction of dyskinesias. Dyskinesias and the abnormal lowering of striatal cGMP and cAMP after levodopa were prevented by pretreatment with the multipotent drug amantadine, outlining the inverse relationship of cAMP/cGMP to dyskinesias. Moreover, dyskinetic animals showed higher striatal hydrolyzing cGMP-phosphodiesterase but not hydrolyzing cAMP-phosphodiesterase activity, suggesting that low cGMP but not cAMP levels could be due to increased catabolism. However, expressions of isozyme phosphodiesterase-1B and -10A highly and specifically located in the basal ganglia were not changed after levodopa in dyskinetic and eukinetic animals: accordingly, selective inhibitors of phosphodiesterase-1B and -10A were ineffective on levodopa dyskinesias. Therefore, the isozyme(s) expressing higher cGMP-phosphodiesterase activity in the striatum of dyskinetic animal should be determined. These observations suggest that dopamine-mediated processes of synthesis and/or degradation of cAMP/cGMP could be acutely impaired in levodopa dyskinesias, opening new ways to understanding physiopathology and treatment.

Original languageEnglish
Pages (from-to)44-56
Number of pages13
JournalNeurochemistry International
Volume79
DOIs
Publication statusPublished - 2014

Fingerprint

Putamen
Dyskinesias
Levodopa
Down-Regulation
Phosphoric Diester Hydrolases
Corpus Striatum
Dopamine
Isoenzymes
Amantadine
Phosphodiesterase Inhibitors
Microdialysis
Second Messenger Systems
Basal Ganglia
Pharmaceutical Preparations

Keywords

  • Amantadine
  • cAMP
  • cGMP
  • Levodopa dyskinesia
  • Parkinson disease
  • Phopsphodiesterase

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology
  • Medicine(all)

Cite this

Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats : Reduced synthesis or increased catabolism? / Sancesario, Giuseppe; Morrone, Luigi Antonio; D'Angelo, Vincenza; Castelli, Valentina; Ferrazzoli, Davide; Sica, Francesco; Martorana, Alessandro; Sorge, Roberto; Cavaliere, Federica; Bernardi, Giorgio; Giorgi, Mauro.

In: Neurochemistry International, Vol. 79, 2014, p. 44-56.

Research output: Contribution to journalArticle

Sancesario, G, Morrone, LA, D'Angelo, V, Castelli, V, Ferrazzoli, D, Sica, F, Martorana, A, Sorge, R, Cavaliere, F, Bernardi, G & Giorgi, M 2014, 'Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism?', Neurochemistry International, vol. 79, pp. 44-56. https://doi.org/10.1016/j.neuint.2014.10.004
Sancesario, Giuseppe ; Morrone, Luigi Antonio ; D'Angelo, Vincenza ; Castelli, Valentina ; Ferrazzoli, Davide ; Sica, Francesco ; Martorana, Alessandro ; Sorge, Roberto ; Cavaliere, Federica ; Bernardi, Giorgio ; Giorgi, Mauro. / Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats : Reduced synthesis or increased catabolism?. In: Neurochemistry International. 2014 ; Vol. 79. pp. 44-56.
@article{57124ccfbf0d4802b7c2967659422a56,
title = "Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: Reduced synthesis or increased catabolism?",
abstract = "Second messenger cAMP and cGMP represent a key step in the action of dopamine that modulates directly or indirectly their synthesis. We aimed to verify whether levodopa-induced dyskinesias are associated with changes of the time course of levodopa/dopamine stimulated cAMP and cGMP levels, and/or with changes of their catabolism by phosphodiesterase activity in rats with experimental hemiparkinsonism. Microdialysis and tissue homogenates of the striatal tissues demonstrated that extracellular and intracellular cAMP/cGMP levels were lower in dyskinetic animals during the increasing phase of dyskinesias compared to eukinetic animals, but cAMP/cGMP levels increased in dyskinetic animals during the phase of decreasing and extinction of dyskinesias. Dyskinesias and the abnormal lowering of striatal cGMP and cAMP after levodopa were prevented by pretreatment with the multipotent drug amantadine, outlining the inverse relationship of cAMP/cGMP to dyskinesias. Moreover, dyskinetic animals showed higher striatal hydrolyzing cGMP-phosphodiesterase but not hydrolyzing cAMP-phosphodiesterase activity, suggesting that low cGMP but not cAMP levels could be due to increased catabolism. However, expressions of isozyme phosphodiesterase-1B and -10A highly and specifically located in the basal ganglia were not changed after levodopa in dyskinetic and eukinetic animals: accordingly, selective inhibitors of phosphodiesterase-1B and -10A were ineffective on levodopa dyskinesias. Therefore, the isozyme(s) expressing higher cGMP-phosphodiesterase activity in the striatum of dyskinetic animal should be determined. These observations suggest that dopamine-mediated processes of synthesis and/or degradation of cAMP/cGMP could be acutely impaired in levodopa dyskinesias, opening new ways to understanding physiopathology and treatment.",
keywords = "Amantadine, cAMP, cGMP, Levodopa dyskinesia, Parkinson disease, Phopsphodiesterase",
author = "Giuseppe Sancesario and Morrone, {Luigi Antonio} and Vincenza D'Angelo and Valentina Castelli and Davide Ferrazzoli and Francesco Sica and Alessandro Martorana and Roberto Sorge and Federica Cavaliere and Giorgio Bernardi and Mauro Giorgi",
year = "2014",
doi = "10.1016/j.neuint.2014.10.004",
language = "English",
volume = "79",
pages = "44--56",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats

T2 - Reduced synthesis or increased catabolism?

AU - Sancesario, Giuseppe

AU - Morrone, Luigi Antonio

AU - D'Angelo, Vincenza

AU - Castelli, Valentina

AU - Ferrazzoli, Davide

AU - Sica, Francesco

AU - Martorana, Alessandro

AU - Sorge, Roberto

AU - Cavaliere, Federica

AU - Bernardi, Giorgio

AU - Giorgi, Mauro

PY - 2014

Y1 - 2014

N2 - Second messenger cAMP and cGMP represent a key step in the action of dopamine that modulates directly or indirectly their synthesis. We aimed to verify whether levodopa-induced dyskinesias are associated with changes of the time course of levodopa/dopamine stimulated cAMP and cGMP levels, and/or with changes of their catabolism by phosphodiesterase activity in rats with experimental hemiparkinsonism. Microdialysis and tissue homogenates of the striatal tissues demonstrated that extracellular and intracellular cAMP/cGMP levels were lower in dyskinetic animals during the increasing phase of dyskinesias compared to eukinetic animals, but cAMP/cGMP levels increased in dyskinetic animals during the phase of decreasing and extinction of dyskinesias. Dyskinesias and the abnormal lowering of striatal cGMP and cAMP after levodopa were prevented by pretreatment with the multipotent drug amantadine, outlining the inverse relationship of cAMP/cGMP to dyskinesias. Moreover, dyskinetic animals showed higher striatal hydrolyzing cGMP-phosphodiesterase but not hydrolyzing cAMP-phosphodiesterase activity, suggesting that low cGMP but not cAMP levels could be due to increased catabolism. However, expressions of isozyme phosphodiesterase-1B and -10A highly and specifically located in the basal ganglia were not changed after levodopa in dyskinetic and eukinetic animals: accordingly, selective inhibitors of phosphodiesterase-1B and -10A were ineffective on levodopa dyskinesias. Therefore, the isozyme(s) expressing higher cGMP-phosphodiesterase activity in the striatum of dyskinetic animal should be determined. These observations suggest that dopamine-mediated processes of synthesis and/or degradation of cAMP/cGMP could be acutely impaired in levodopa dyskinesias, opening new ways to understanding physiopathology and treatment.

AB - Second messenger cAMP and cGMP represent a key step in the action of dopamine that modulates directly or indirectly their synthesis. We aimed to verify whether levodopa-induced dyskinesias are associated with changes of the time course of levodopa/dopamine stimulated cAMP and cGMP levels, and/or with changes of their catabolism by phosphodiesterase activity in rats with experimental hemiparkinsonism. Microdialysis and tissue homogenates of the striatal tissues demonstrated that extracellular and intracellular cAMP/cGMP levels were lower in dyskinetic animals during the increasing phase of dyskinesias compared to eukinetic animals, but cAMP/cGMP levels increased in dyskinetic animals during the phase of decreasing and extinction of dyskinesias. Dyskinesias and the abnormal lowering of striatal cGMP and cAMP after levodopa were prevented by pretreatment with the multipotent drug amantadine, outlining the inverse relationship of cAMP/cGMP to dyskinesias. Moreover, dyskinetic animals showed higher striatal hydrolyzing cGMP-phosphodiesterase but not hydrolyzing cAMP-phosphodiesterase activity, suggesting that low cGMP but not cAMP levels could be due to increased catabolism. However, expressions of isozyme phosphodiesterase-1B and -10A highly and specifically located in the basal ganglia were not changed after levodopa in dyskinetic and eukinetic animals: accordingly, selective inhibitors of phosphodiesterase-1B and -10A were ineffective on levodopa dyskinesias. Therefore, the isozyme(s) expressing higher cGMP-phosphodiesterase activity in the striatum of dyskinetic animal should be determined. These observations suggest that dopamine-mediated processes of synthesis and/or degradation of cAMP/cGMP could be acutely impaired in levodopa dyskinesias, opening new ways to understanding physiopathology and treatment.

KW - Amantadine

KW - cAMP

KW - cGMP

KW - Levodopa dyskinesia

KW - Parkinson disease

KW - Phopsphodiesterase

UR - http://www.scopus.com/inward/record.url?scp=84909977969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909977969&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2014.10.004

DO - 10.1016/j.neuint.2014.10.004

M3 - Article

C2 - 25452081

AN - SCOPUS:84909977969

VL - 79

SP - 44

EP - 56

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

ER -